# Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma

> **NCT07389876** · — · RECRUITING · sponsor: **Fudan University** · enrollment: 250 (estimated)

## Conditions studied

- Gastric Cancer
- Second-line Treatment

## Interventions

- **DRUG:** Albumin-bound Paclitaxel
- **DRUG:** Immune Checkpoint Inhibitor
- **DRUG:** Anti-angiogenic drug
- **DRUG:** Trastuzumab emtansine

## Key facts

- **NCT ID:** NCT07389876
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07389876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07389876, "Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07389876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*